Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet.
Rusconi S, Innocenti A, Vullo D, Mastrolorenzo A, Scozzafava A, Supuran CT. Rusconi S, et al. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7. doi: 10.1016/j.bmcl.2004.09.064. Bioorg Med Chem Lett. 2004. PMID: 15501037
The cytosolic isozyme hCA II was weakly inhibited by all the investigated anions, with carbamoyl phosphate showing a K(I) of 0.31 mM. ...The mitochondrial isozyme hCA V was weakly inhibited by all phosphates/phosphonates, except carbamoyl phosphate, which showed a K …
The cytosolic isozyme hCA II was weakly inhibited by all the investigated anions, with carbamoyl phosphate showing a K(I) of 0.31 mM. …
Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
Vullo D, Leewattanapasuk W, Mühlschlegel FA, Mastrolorenzo A, Capasso C, Supuran CT. Vullo D, et al. Among authors: mastrolorenzo a. Bioorg Med Chem Lett. 2013 May 1;23(9):2647-52. doi: 10.1016/j.bmcl.2013.02.092. Epub 2013 Mar 1. Bioorg Med Chem Lett. 2013. PMID: 23511020
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.
Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT. Mastrolorenzo A, et al. Curr Med Chem. 2007;14(26):2734-48. doi: 10.2174/092986707782360141. Curr Med Chem. 2007. PMID: 18045120 Review.
This therapy involves the use of at least three agents from two distinct classes of antivirals: a protease inhibitor (PI) in combination with two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs), or a non-nucleoside reverse transcriptase inhibitor ( …
This therapy involves the use of at least three agents from two distinct classes of antivirals: a protease inhibitor (PI) in combinat …
An update in the development of HIV entry inhibitors.
Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. Rusconi S, et al. Curr Top Med Chem. 2007;7(13):1273-89. doi: 10.2174/156802607781212239. Curr Top Med Chem. 2007. PMID: 17627557 Review.
Intense research led to a wide range of effective compounds that are able to inhibit these initial steps of viral replication. ...Many HIV entry and fusion inhibitors are currently investigated in controlled clinical trials, and there are a number of them that is bi …
Intense research led to a wide range of effective compounds that are able to inhibit these initial steps of viral replication. ...Man …
Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies.
Temperini C, Innocenti A, Mastrolorenzo A, Scozzafava A, Supuran CT. Temperini C, et al. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4866-72. doi: 10.1016/j.bmcl.2007.06.044. Epub 2007 Jun 14. Bioorg Med Chem Lett. 2007. PMID: 17588751
Sulthiame, a clinically used antiepileptic, was investigated for its interaction with 12 catalytically active mammalian carbonic anhydrase (CA, EC 4.2.1.1) isoforms. The drug is a potent inhibitor of CA II, VII, IX, and XII (K(I)s of 6-56 nM), and a medium po …
Sulthiame, a clinically used antiepileptic, was investigated for its interaction with 12 catalytically active mammalian carbonic anhy …
New advances in HIV entry inhibitors development.
Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. Rusconi S, et al. Curr Drug Targets Infect Disord. 2004 Dec;4(4):339-55. doi: 10.2174/1568005043340498. Curr Drug Targets Infect Disord. 2004. PMID: 15578975 Review.
Recently, a third family of antivirals started to be used clinically (in addition to the reverse transcriptase and protease inhibitors), with the advent of enfuvirtide (T20), the first fusion inhibitor to be approved as an anti-HIV agent. ...Many HIV entry and fusion inhib …
Recently, a third family of antivirals started to be used clinically (in addition to the reverse transcriptase and protease inhibitor …
COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents.
Supuran CT, Casini A, Mastrolorenzo A, Scozzafava A. Supuran CT, et al. Mini Rev Med Chem. 2004 Aug;4(6):625-32. doi: 10.2174/1389557043403792. Mini Rev Med Chem. 2004. PMID: 15279596
A recently developed class of pharmacological agents incorporating primary sulfamoyl moieties in their molecule is constituted by the COX-2 selective inhibitors, with at least two clinically used drugs, celecoxib and valdecoxib. ...
A recently developed class of pharmacological agents incorporating primary sulfamoyl moieties in their molecule is constituted by the
Antiviral sulfonamide derivatives.
Supuran CT, Innocenti A, Mastrolorenzo A, Scozzafava A. Supuran CT, et al. Mini Rev Med Chem. 2004 Feb;4(2):189-200. doi: 10.2174/1389557043487402. Mini Rev Med Chem. 2004. PMID: 14965291 Review.
A large number of structurally novel sulfonamide derivatives have ultimately been reported to show substantial antiviral activity in vitro and in vivo. ...Another approach to inhibit the growth of retroviruses, including HIV, targets the ejection of zinc ions from critical
A large number of structurally novel sulfonamide derivatives have ultimately been reported to show substantial antiviral activity in
Anticancer and antiviral sulfonamides.
Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. Scozzafava A, et al. Curr Med Chem. 2003 Jun;10(11):925-53. doi: 10.2174/0929867033457647. Curr Med Chem. 2003. PMID: 12678681 Review.
A large number of structurally novel sulfonamide derivatives have ultimately been reported to show substantial antitumor activity in vitro and in vivo. Although they have a common chemical motif of aromatic/heterocyclic or amino acid sulfonamide, there are a
A large number of structurally novel sulfonamide derivatives have ultimately been reported to show substantial antitumor activity in
Sulfonamides and sulfonylated derivatives as anticancer agents.
Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Casini A, et al. Curr Cancer Drug Targets. 2002 Mar;2(1):55-75. doi: 10.2174/1568009023334060. Curr Cancer Drug Targets. 2002. PMID: 12188921 Review.
A host of structurally novel sulfonamide derivatives have recently been reported to show substantial antitumor activity in vitro and/or in vivo. Although they have a common chemical motif of aromatic/heterocyclic sulfonamide, there are a variety of mechanisms
A host of structurally novel sulfonamide derivatives have recently been reported to show substantial antitumor activity in vitro and/
52 results
Jump to page
Feedback